Arrowhead Pharmaceuticals, Inc. (0HI3.L)
0HI3.L Stock Price Chart
Explore Arrowhead Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze 0HI3.L price movements and trends.
0HI3.L Company Profile
Discover essential business fundamentals and corporate details for Arrowhead Pharmaceuticals, Inc. (0HI3.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Jan 2018
Employees
609.00
Website
https://arrowheadpharma.comCEO
Christopher R. Anzalone
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
0HI3.L Financial Timeline
Browse a chronological timeline of Arrowhead Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 9 Feb 2026
Upcoming earnings on 24 Nov 2025
Upcoming earnings on 6 Aug 2025
Revenue estimate is $29.01M.
Earnings released on 12 May 2025
EPS came in at $2.75 surpassing the estimated -$0.44 by +722.20%, while revenue for the quarter reached $542.71M, beating expectations by +366.77%.
Earnings released on 10 Feb 2025
EPS came in at -$1.39 falling short of the estimated -$0.48 by -192.10%, while revenue for the quarter reached $2.50M, missing expectations by -86.88%.
Earnings released on 27 Nov 2024
EPS came in at -$1.36 falling short of the estimated -$1.12 by -21.38%.
Earnings released on 9 Aug 2024
EPS came in at -$1.38 falling short of the estimated -$0.53 by -159.99%.
Earnings released on 10 May 2024
EPS came in at -$1.02 falling short of the estimated -$0.47 by -115.37%.
Earnings released on 6 Mar 2024
EPS came in at -$1.24 falling short of the estimated -$0.80 by -54.42%, while revenue for the quarter reached $3.55M, missing expectations by -89.52%.
Earnings released on 30 Nov 2023
EPS came in at -$1.02 falling short of the estimated -$0.61 by -67.94%, while revenue for the quarter reached $16.10M, missing expectations by -63.93%.
Earnings released on 8 Aug 2023
EPS came in at -$0.96 falling short of the estimated -$0.57 by -68.99%, while revenue for the quarter reached $15.83M, missing expectations by -65.16%.
Earnings released on 3 May 2023
EPS came in at $0.45 surpassing the estimated -$0.62 by +172.83%, while revenue for the quarter reached $146.27M, beating expectations by +221.61%.
Earnings released on 7 Feb 2023
EPS came in at -$0.39 falling short of the estimated $0.37 by -205.36%, while revenue for the quarter reached $62.55M, missing expectations by -61.51%.
Earnings released on 29 Nov 2022
EPS came in at -$0.81 falling short of the estimated -$0.58 by -38.19%, while revenue for the quarter reached $31.58M, missing expectations by -37.22%.
Earnings released on 30 Jun 2022
EPS came in at -$0.68 falling short of the estimated -$0.57 by -19.82%, while revenue for the quarter reached $32.41M, missing expectations by -29.16%.
Earnings released on 31 Mar 2022
EPS came in at $0.41 surpassing the estimated $0.14 by +183.71%, while revenue for the quarter reached $151.81M, beating expectations by +24.28%.
Earnings released on 31 Dec 2021
EPS came in at -$0.60, while revenue for the quarter reached $27.44M.
Earnings released on 30 Sept 2021
EPS came in at -$0.61 falling short of the estimated -$0.45 by -35.94%, while revenue for the quarter reached $38.28M, missing expectations by -19.93%.
Earnings released on 30 Jun 2021
EPS came in at -$0.29, while revenue for the quarter reached $45.89M.
Earnings released on 5 May 2021
EPS came in at -$0.20, while revenue for the quarter reached $21.30M.
Earnings released on 31 Mar 2021
EPS came in at -$0.26, while revenue for the quarter reached $32.81M.
Earnings released on 30 Sept 2020
EPS came in at -$0.47, while revenue for the quarter reached $7.63M.
0HI3.L Stock Performance
Access detailed 0HI3.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.